| Theme | Liver and Immunology 2019 | |
|---|---|---|
| Title | Immunotherapy for Hepatocellular Carcinoma Using TCR—gene Engineered T Cells | |
| Publish Date | 2019/05 | |
| Author | Eishiro Mizukoshi | Department of Gastroenterology, Graduate School of Medicine, Kanazawa University |
| Author | Hidetoshi Nakagawa | Department of Gastroenterology, Graduate School of Medicine, Kanazawa University |
| Author | Toshikatsu Tamai | Department of Gastroenterology, Graduate School of Medicine, Kanazawa University |
| Author | Shuichi Kaneko | Department of Gastroenterology, Graduate School of Medicine, Kanazawa University |
| [ Summary ] | In the area of cancer immunotherapy, treatment of childhood leukemia using CAR‒T cells was approved by the FDA in the United States. This therapy targets antigens expressed on the cell surface, and specific antigens suitable for the same therapy are not identified in hepatocellular carcinoma (HCC), which is considered to be difficult to apply. On the other hand, when targeting tumor‒associated antigen‒derived epitope expressed in HCC, genetically engineered T cell therapy using T cell receptor (TCR) is possible. So far, we have uniquely identified tumor‒associated antigen‒derived epitopes specific for HCC and have developed a rapid TCR cloning system as a basic technology for producing genetically engineered T cells. In this paper, we describe genetically engineered T cell therapy using TCRs specific for tumor associated antigen‒derived epitopes expressed in HCC. | |